James Kyle Bryan

Phase Ib Trial of the Toll-like Receptor 8 Agonist, Motolimod (VTX-2337), Combined with Cetuximab in Patients with Recurrent or Metastatic SCCHN

Laura Q.M. Chow, Chihiro Morishima, Keith D. Eaton et al. · Clinical Cancer Research · 2016 · 126 citations

Medicine, Oncology, Pharmacology +17

Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck

Robert L. Ferris, Nabil F. Saba, Barbara J. Gitlitz et al. · JAMA Oncology · 2018 · 111 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

Phase Ib Study of Immune Biomarker Modulation with Neoadjuvant Cetuximab and TLR8 Stimulation in Head and Neck Cancer to Overcome Suppressive Myeloid Signals

Gulidanna Shayan, Benjamin Kansy, Sandra P. Gibson et al. · Clinical Cancer Research · 2017 · 80 citations · Full text

Medicine, Immunology, Oncology +17

Late-Stage Cancer Patients Remain Highly Responsive to Immune Activation by the Selective TLR8 Agonist Motolimod (VTX-2337)

Gregory N. Dietsch, Tressa D. Randall, Raphaël Gottardo et al. · Clinical Cancer Research · 2015 · 39 citations

Life Sciences, Immunology, Pharmacology +17